Lates News

According to a news flash from Every AI, on April 28th, China Post Securities issued a research report giving a "buy" rating to BluBio (603739.SH). The main reasons for the rating include: 1) the main business operation is stable, with structural differentiation in sub-sectors becoming more prominent; 2) deep cultivation of core tracks, leading the industry with technological advantages; 3) continuous increase in research and development investment, with a solid technological innovation barrier. (Daily Economic News)